UY25992A1 - Procedimiento para preparar inhibidores de tace (enzima conversora del factor alfa de necrosis tumoral) - Google Patents

Procedimiento para preparar inhibidores de tace (enzima conversora del factor alfa de necrosis tumoral)

Info

Publication number
UY25992A1
UY25992A1 UY25992A UY25992A UY25992A1 UY 25992 A1 UY25992 A1 UY 25992A1 UY 25992 A UY25992 A UY 25992A UY 25992 A UY25992 A UY 25992A UY 25992 A1 UY25992 A1 UY 25992A1
Authority
UY
Uruguay
Prior art keywords
sup
conversing
enzyme
preparing
procedure
Prior art date
Application number
UY25992A
Other languages
English (en)
Inventor
Michael Anthony Letavic
Mark Carl Noe
Kim Francis Mcclure
Louis Stanley Chupak
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of UY25992A1 publication Critical patent/UY25992A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/96—Sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/12—1,4-Thiazines; Hydrogenated 1,4-thiazines not condensed with other rings

Abstract

Procedimiento para preparar derivados de hidroxiamida heterocíclicos de fórmula (I) en donde: X es O, S, SO, SO2 o NR7 (R7 es H o alquilo); R1, R2, R3, R4, R5, Y R6 se seleccionan del grupo integrado por hidrógeno, hidroxi, ciano, alquilo, alquenilo, alquinilo, alquilamino, tioalquilo, alcoxi, perfluoroalquilo, arilo, heteroarilo, arilamino, tioarilo, ariloxi, piperidilo, tioacilo, y CO2H; Q es ariloalcoxiarilo, ariloalcoxiheteroarilo, heteroariloalcoxiarilo, o heteroariloalcoxiheteroarilo; y a composiciones farmacéuticas que comprenden tales derivados y al uso de tales derivados en el tratamiento de la artritis, cáncer y otras enfermedades que implican una producción / liberación no regulada de reprolisinas como alfa-TNF (factor alfa de necrosis tumoral) y otras enfermedades caracterizadas por actividad de metaloproteinasas de la matriz. Además, los compuestos de la presente invención se pueden usar en terapia de combinación con fármacos antiinflamatorios no esteroides (AINEs), inhibidores de la COX-2 y analgésicos convencionales, y en el tratamiento del cáncer, en combinación con fármacos citotóxicos como adriamicina, daunomicina, cisplatino, etopósido, taxol, taxótero y otros alcaloides como vincristina. Ej. no limitante: hidroxiamida del ácido (2S,3S) 4-[4-(3,5-difluorobenciloxi)-bencenosulfonil]-2-metiltiomorfolin-3-carboxílico.
UY25992A 1998-08-12 2000-01-28 Procedimiento para preparar inhibidores de tace (enzima conversora del factor alfa de necrosis tumoral) UY25992A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US9625698P 1998-08-12 1998-08-12

Publications (1)

Publication Number Publication Date
UY25992A1 true UY25992A1 (es) 2000-03-31

Family

ID=22256553

Family Applications (1)

Application Number Title Priority Date Filing Date
UY25992A UY25992A1 (es) 1998-08-12 2000-01-28 Procedimiento para preparar inhibidores de tace (enzima conversora del factor alfa de necrosis tumoral)

Country Status (15)

Country Link
US (2) US20030181441A1 (es)
EP (1) EP1104412B1 (es)
JP (1) JP3623448B2 (es)
AT (1) ATE297908T1 (es)
AU (1) AU4925099A (es)
BR (1) BR9912944A (es)
CA (1) CA2340182A1 (es)
DE (1) DE69925840T2 (es)
ES (1) ES2242402T3 (es)
GT (1) GT199900132A (es)
MA (1) MA26674A1 (es)
PA (1) PA8479901A1 (es)
TN (1) TNSN99157A1 (es)
UY (1) UY25992A1 (es)
WO (1) WO2000009492A1 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6406901B1 (en) 1995-06-08 2002-06-18 Immunex Corporation TNF-a converting enzyme
US6833373B1 (en) 1998-12-23 2004-12-21 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
EP1081137A1 (en) 1999-08-12 2001-03-07 Pfizer Products Inc. Selective inhibitors of aggrecanase in osteoarthritis treatment
GB9922825D0 (en) * 1999-09-25 1999-11-24 Smithkline Beecham Biolog Medical use
GB0004531D0 (en) * 2000-02-25 2000-04-19 Richards Andrew J M The treatment of respiratory diseases
US6458822B2 (en) 2000-03-13 2002-10-01 Pfizer Inc. 2-oxo-imidazolidine-4-carboxylic acid hydroxamide compounds that inhibit matrix metalloproteinases
EP1138680A1 (en) * 2000-03-29 2001-10-04 Pfizer Products Inc. Gem substituted sulfonyl hydroxamic acids as MMP inhibitors
MXPA01013326A (es) 2001-02-14 2002-08-26 Warner Lambert Co Bifenil sulfonamidas utiles como inhibisdores de metaloproteinasa de matriz.
US7354923B2 (en) * 2001-08-10 2008-04-08 Palatin Technologies, Inc. Piperazine melanocortin-specific compounds
CA2462200A1 (en) 2001-08-10 2003-02-20 Palatin Technologies, Inc. Peptidomimetics of biologically active metallopeptides
US7718802B2 (en) 2001-08-10 2010-05-18 Palatin Technologies, Inc. Substituted melanocortin receptor-specific piperazine compounds
US7655658B2 (en) 2001-08-10 2010-02-02 Palatin Technologies, Inc. Thieno [2,3-D]pyrimidine-2,4-dione melanocortin-specific compounds
US7456184B2 (en) * 2003-05-01 2008-11-25 Palatin Technologies Inc. Melanocortin receptor-specific compounds
US7732451B2 (en) 2001-08-10 2010-06-08 Palatin Technologies, Inc. Naphthalene-containing melanocortin receptor-specific small molecule
AUPR726201A0 (en) * 2001-08-24 2001-09-20 Fujisawa Pharmaceutical Co., Ltd. New use of a cyclic compound
EP1511488B1 (en) 2002-06-12 2013-05-22 Symphony Evolution, Inc. Human adam-10 inhibitors
US7199155B2 (en) 2002-12-23 2007-04-03 Wyeth Holdings Corporation Acetylenic aryl sulfonate hydroxamic acid TACE and matrix metalloproteinase inhibitors
MXPA05010793A (es) 2003-04-09 2005-12-05 Millennium Pharm Inc Beta-carbolinas utiles para tratar enfermedades inflamatorias.
US7968548B2 (en) 2003-05-01 2011-06-28 Palatin Technologies, Inc. Melanocortin receptor-specific piperazine compounds with diamine groups
US7727991B2 (en) 2003-05-01 2010-06-01 Palatin Technologies, Inc. Substituted melanocortin receptor-specific single acyl piperazine compounds
US7727990B2 (en) 2003-05-01 2010-06-01 Palatin Technologies, Inc. Melanocortin receptor-specific piperazine and keto-piperazine compounds
TW200539880A (en) 2004-04-09 2005-12-16 Millennium Pharm Inc Beta-carbolines useful for treating inflammatory disease
US7709484B1 (en) 2004-04-19 2010-05-04 Palatin Technologies, Inc. Substituted melanocortin receptor-specific piperazine compounds
WO2007016597A2 (en) * 2005-07-29 2007-02-08 The Regents Of The University Of California Targeting tnf-alpha converting enzyme (tace)-dependent growth factor shedding in cancer therapy
EP2041181B1 (en) * 2006-06-08 2011-05-18 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Specific protease inhibitors and their use in cancer therapy
US7834017B2 (en) 2006-08-11 2010-11-16 Palatin Technologies, Inc. Diamine-containing, tetra-substituted piperazine compounds having identical 1- and 4-substituents
IT1404729B1 (it) * 2011-01-27 2013-11-29 Univ Pisa Inibitori altamente selettivi dell'attivita' di adams
WO2013050476A1 (en) * 2011-10-04 2013-04-11 Institut National De La Sante Et De La Recherche Medicale (Inserm) New apoptosis inducing compounds
CN111500721B (zh) * 2020-04-20 2022-11-29 青岛大学附属医院 Tace在腹主动脉瘤腔内修复术后内漏诊断中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6153757A (en) * 1995-12-08 2000-11-28 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors and intermediates useful for their preparation
US5753653A (en) * 1995-12-08 1998-05-19 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
CA2264045A1 (en) * 1996-08-28 1998-03-05 Randall Stryker Matthews Heterocyclic metalloprotease inhibitors
EP0948489A1 (en) * 1996-12-17 1999-10-13 Fujisawa Pharmaceutical Co., Ltd. Piperazine compounds as inhibitors of mmp or tnf
BR9807678A (pt) * 1997-02-11 2000-02-15 Pfizer Derivados de ácidos arilsulfonil-hidroxâmicos
EP1081137A1 (en) * 1999-08-12 2001-03-07 Pfizer Products Inc. Selective inhibitors of aggrecanase in osteoarthritis treatment

Also Published As

Publication number Publication date
BR9912944A (pt) 2001-05-08
GT199900132A (es) 2001-02-02
AU4925099A (en) 2000-03-06
MA26674A1 (fr) 2004-12-20
JP3623448B2 (ja) 2005-02-23
EP1104412B1 (en) 2005-06-15
US20050215549A1 (en) 2005-09-29
JP2003526604A (ja) 2003-09-09
CA2340182A1 (en) 2000-02-24
TNSN99157A1 (fr) 2005-11-10
DE69925840D1 (de) 2005-07-21
PA8479901A1 (es) 2000-05-24
EP1104412A1 (en) 2001-06-06
ES2242402T3 (es) 2005-11-01
ATE297908T1 (de) 2005-07-15
US20030181441A1 (en) 2003-09-25
WO2000009492A1 (en) 2000-02-24
DE69925840T2 (de) 2006-05-04

Similar Documents

Publication Publication Date Title
UY25992A1 (es) Procedimiento para preparar inhibidores de tace (enzima conversora del factor alfa de necrosis tumoral)
YU5201A (sh) Derivati hidroksipipekolathidroksamske kiseline kao inhibitori mmp
BR0101241A (pt) ácidos hidroxâmicos gem substituìdos
TR199901849T2 (xx) Arils�lfonilamino hidroksamik asit t�revleri.
BRPI0413452A (pt) composto, composição farmacêutica, kit, artigo de fabricação, e, métodos de inibir dpp-iv, terapêutico e de tratar um estado de doença, cáncer, distúrbios autoimunes, uma condição einfecção por hiv
BR9807824A (pt) Derivados de n-hidróxi-beta-sulfonil-propionamida e seu uso como inibidores de metaloproteinases de matriz
EA199900036A1 (ru) Ингибиторы металлопротеаз матрикса на основе фосфинатов, фармацевтическая композиция, способ лечения
GEP20053692B (en) Substituted Alkylamine Derivatives and Methods of Use
IS6329A (is) Lyf til að meðhöndla illkynja æxli
AU2006273692A8 (en) 1,4-Dihydropyridine-fused heterocycles, process for preparing the same, use and compositions containing them
AU2002352708A1 (en) Cytotoxic agents
PT1181286E (pt) Hidroxamidas de acido 3-(arilsulfonilamino)-tetrahidropirano-3-carboxilico
DE60005818D1 (de) 3-(arylsulfonylamino)-tetrahydrofuran-3-carbonsäure-hydroxamide
AU3282300A (en) Molecules for the treatment and diagnosis of tumors
ECSP993099A (es) Inhibidores de tace
ECSP993100A (es) Derivados de acido hidroxi - pipecolato hidroxamico

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20100518